HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026
BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced the presentation of preclinical data from the Company's interferon...
BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced the presentation of preclinical data from the Company's interferon...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.